Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 5/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | STK4 | Q13043 | 2/20 | 0.35 |
| ▸ | STK3 | Q13188 | 2/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.35 |
| ▸ | STK26 | Q9P289 | 2/20 | 0.35 |
| ▸ | STK24 | Q9Y6E0 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190895 | 1.00 | ERN1 (0.53) | ERN1MAPK14BRAFRIPK2ACVR1 | |
| SCHEMBL22200422 | 0.92 | ERN1 (0.53) | ERN1MAPK14BRAFSTK4STK3 | |
| Hydrochloric Acid SCHEMBL22191006 | 0.91 | ERN1 (0.52) | ERN1MAPK14BRAFSTK4STK3 | |
| Hydrochloric Acid SCHEMBL29353020 | 0.91 | ERN1 (0.52) | ERN1MAPK14BRAFSTK4STK3 | |
| SCHEMBL22190623 | 0.88 | ERN1 (0.64) | ERN1MAPK14BRAF | |
| SCHEMBL29356695 | 0.88 | ERN1 (0.64) | ERN1MAPK14BRAF | |
| SCHEMBL22200523 | 0.86 | ERN1 (0.58) | ERN1MAPK14BRAF | |
| SCHEMBL22200520 | 0.86 | ERN1 (0.58) | ERN1MAPK14BRAF | |
| SCHEMBL22200604 | 0.86 | ERN1 (0.58) | ERN1MAPK14BRAF | |
| SCHEMBL22200525 | 0.86 | ERN1 (0.58) | ERN1MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885MAPK14 2813/4885BRAF 563/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | ERN1 3167/4885MAPK14 2813/4885BRAF 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.